DarioHealth Prices $23.5 Million Stock Offering at Market Value

July 23, 2026
DarioHealth Corp. announced the pricing of a $23.5 million registered direct offering of common stock, with shares priced at $6.80 each. The offering is expected to close on or about July 23, 2026, subject to customary conditions.

DarioHealth Corp. announced in a press release that it has priced a registered direct offering of approximately $23.5 million in common stock at $6.80 per share. The offering involves the sale of 3,454,559 shares to existing institutional investors and new participants.

A member of DarioHealth's board of directors also took part, purchasing 14,430 shares at $6.93 per share. A.G.P./Alliance Global Partners is acting as the sole placement agent for the transaction.

Gross proceeds from the offering are expected to be about $23.5 million before fees and expenses. The closing is anticipated on or about July 23, 2026, subject to standard closing conditions. DarioHealth plans to use the funds for working capital, investments, acquisitions, and general corporate purposes.

The securities are being issued under an effective shelf registration statement on Form S-3 (File No. 333-294454) that became effective on March 27, 2026. A prospectus supplement will be filed with the U.S. Securities and Exchange Commission and made available through its website.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

AI Funding News Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Funding

09/08
Mistral AI Raises €3 Billion at €21 Billion Valuation
09/08
Veridue Raises $4 Million for AI Energy Due Diligence
09/08
Zeit AI raises €5 million for autonomous data engineering agent
09/08
AI Score Raises $5.4 Million for AI Governance Platform
09/08
Atira Raises $17.5 Million for Industrial Sales AI

More from: Life Sciences

09/08
Flysound Launches B02 AI Hearing Aid in the US
09/07
Rentosertib Study Finds Lower Predicted Biological Age in IPF Trial
09/07
Sky Labs Presents CART Blood Pressure Studies at ESC 2026
09/05
HoneyNaps Develops Wireless Sleep Monitoring System With Four Skin Patches
09/05
Carestream Updates DRX LC Detector With AI Noise Reduction

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more

You May Also Like